Cumberland Pharmaceuticals Inc. Share Price
NASDAQ: CPIX | Micro CapCumberland Pharmaceuticals Inc. Stock Performance
Open $7.57 | Prev. Close $7.54 | Circuit Range N/A |
Day Range $7.57 - $7.67 | Year Range $1.92 - $8.19 | Volume 838 |
Average Traded $7.61 |
Cumberland Pharmaceuticals Inc. Share Price Today
As of 10 August 2026, Cumberland Pharmaceuticals Inc.'s share price is $7.83. The stock opened at $7.57, compared to its previous close of $7.54. During today's trading session, Cumberland Pharmaceuticals Inc.'s share price traded between $7.57 and $7.67, with an average price of $7.62. Over the past 52 weeks, the stock has recorded a high of $8.19 and a low of $1.92. In terms of performance, Cumberland Pharmaceuticals Inc.'s share price has risen by 61.88% over the last six months and is up 126.45% on a year-on-year basis.
Cumberland Pharmaceuticals Inc. Share Price Chart
Cumberland Pharmaceuticals Inc. Stock Fundamentals & Key Indicators
Market Cap $116.39M | PE Ratio (TTM) -41.24 | Dividend Yield N/A |
EPS (TTM) $-0.19 | Revenue (TTM) $44.52M | Return On Equity (TTM) -11.51% |
Profit Margin -6.43% | Debt to Equity 1.48 | Quarterly Earnings Growth YoY -25.69% |
Cumberland Pharmaceuticals Inc. Quarterly Profit & Loss
All figures in USD
Cumberland Pharmaceuticals Inc. Annual Profit & Loss
All figures in USD
About Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an injection for the prevention of nausea and vomiting for patients receiving chemotherapy treatment; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of the cardiomyopathy associate with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease; and is in Phase II clinical trial for the treatment of systemic sclerosis and idiopathic pulmonary fibrosis. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Cumberland Pharmaceuticals Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $6.01 | $7.67 | +13.55% |
Jul 2026 | $6.58 | $6.75 | +4.08% |
Jun 2026 | $6.04 | $6.49 | +5.19% |
May 2026 | $4.24 | $6.17 | +45.86% |
Apr 2026 | $3.22 | $4.23 | +30.96% |
Mar 2026 | $4.96 | $3.23 | -33.26% |
Feb 2026 | $3.81 | $4.84 | +28.21% |
Jan 2026 | $3.95 | $3.77 | -3.21% |
Dec 2025 | $2.35 | $3.90 | +68.10% |
Nov 2025 | $2.80 | $2.32 | -22.41% |
Oct 2025 | $3.20 | $2.99 | -2.92% |
Sep 2025 | $3.46 | $3.08 | -10.98% |